Filing Analysis
Vistagen Therapeutics announced that two members of its Board of Directors, Ms. Margaret FitzPatrick and Dr. Joanne Curley, have decided not to stand for re-election at the 2026 Annual Meeting of Stockholders.
📋 Key Facts
- Ms. Margaret FitzPatrick notified the company of her decision on June 16, 2026.
- Dr. Joanne Curley notified the company of her decision on June 17, 2026.
- Both directors will continue to serve until the conclusion of their terms at the 2026 Annual Meeting.
Vistagen Therapeutics, Inc. filed a current report to furnish a press release announcing its financial results for the fiscal year ended March 31, 2026.
📋 Key Facts
- The filing date is June 15, 2026.
- The company announced financial results for the fiscal year ending March 31, 2026.
- The financial results were issued via a press release (Exhibit 99.1).
Vistagen Therapeutics announced that its clinical program for fasedienol nasal spray for social anxiety disorder has met the minimum patient exposure requirements as recommended by the ICH E1 international regulatory standard.
📋 Key Facts
- The announcement pertains to fasedienol nasal spray for the acute treatment of social anxiety disorder.
- The company has achieved minimum patient exposures per ICH E1 standards for drugs intended for long-term treatment of non-life-threatening conditions.
- The report was filed on June 9, 2026.
Vistagen Therapeutics, Inc. has appointed Dr. Angel S. Angelov as its new Chief Medical Officer, effective May 18, 2026. Dr. Angelov brings extensive psychiatric and clinical development experience from previous leadership roles at Theranica, Karuna Therapeutics, and Neurocrine Biosciences.
🚩 Red Flags
- The stock option exercise price of $0.5955 indicates the company's common stock is trading below $1.00, which poses a potential risk for Nasdaq minimum bid price compliance.
📋 Key Facts
- Dr. Angel S. Angelov, M.D., MBA, appointed as Chief Medical Officer effective May 18, 2026.
- Dr. Angelov's compensation includes a starting annual base salary of $425,000, a $50,000 signing bonus (paid in two tranches), and a target annual discretionary bonus of 45% of his base salary.
- Granted an inducement stock option to purchase 150,000 shares of common stock at an exercise price of $0.5955 per share, vesting over four years with a one-year cliff.
- Dr. Angelov previously served as CMO at Theranica and held medical affairs leadership roles at Karuna Therapeutics and Neurocrine Biosciences.
Vistagen Therapeutics announced preliminary positive data from the ongoing open-label extension of its PALISADE-3 Phase 3 clinical trial. The study evaluates fasedienol for the acute treatment of social anxiety disorder.
📋 Key Facts
- Preliminary positive data announced on May 12, 2026.
- The data originates from the open-label extension portion of the PALISADE-3 Phase 3 study.
- The drug candidate, fasedienol, is being developed for the acute treatment of social anxiety disorder.
- The company issued a press release (Exhibit 99.1) to disclose these findings.
Vistagen Therapeutics announced the completion of the last patient's last visit in its PALISADE-4 Phase 3 clinical trial. The trial evaluates fasedienol nasal spray for the acute treatment of social anxiety disorder.
📋 Key Facts
- The last patient completed their last visit in the PALISADE-4 Phase 3 clinical trial on May 8, 2026.
- The trial is a randomized, double-blind, placebo-controlled study.
- The study drug, fasedienol, is a nasal spray intended for the acute treatment of social anxiety disorder.
- The company issued a press release (Exhibit 99.1) regarding this milestone.
Vistagen Therapeutics received FDA clearance to proceed with Phase 2 clinical development of its refisolone nasal spray in the U.S. The candidate is a non-hormonal treatment for moderate to severe vasomotor symptoms (hot flashes) associated with menopause.
📋 Key Facts
- Received FDA 'Study May Proceed' letter on April 22, 2026, regarding its U.S. Investigational New Drug (IND) application.
- The product candidate, refisolone nasal spray, is non-hormonal and non-systemic.
- The U.S. Phase 2 development follows successful exploratory Phase 2a studies previously conducted in Mexico.
- The target indication is moderate to severe vasomotor symptoms (hot flashes) due to menopause and premenstrual dysphoric disorder.
Vistagen Therapeutics approved broad-based retention stock option awards for all employees, including five key executive officers, on April 7, 2026. The awards feature a two-year vesting schedule and an exercise price of $0.5358 per share.
🚩 Red Flags
- The exercise price of $0.5358 indicates the stock is trading significantly below the Nasdaq $1.00 minimum bid price requirement, suggesting potential delisting risk.
- Broad-based 'retention' awards often signal internal concerns regarding employee turnover or low morale following share price depreciation.
📋 Key Facts
- Retention awards granted to all employees on April 7, 2026.
- Five named executive officers (CEO, CLO, CCDO, COO, and CFO) each received options for 75,000 shares.
- The exercise price is set at $0.5358 per share.
- Vesting occurs in 25% increments every six months, reaching full vestment on the two-year anniversary.
- The grants were issued under the Company’s Amended and Restated 2019 Omnibus Equity Incentive Plan.
Vistagen Therapeutics notified Nasdaq of non-compliance with Audit Committee requirements following the resignation of director Mary Rotunno. The company currently has only two members on its Audit Committee, falling below the Nasdaq requirement of three independent members.
🚩 Red Flags
- Failure to satisfy Nasdaq continued listing standards regarding board composition.
- Loss of a director (Mary Rotunno) resulting in governance non-compliance.
📋 Key Facts
- The Company notified Nasdaq of non-compliance with Listing Rule 5605(c)(2) on April 1, 2026.
- The non-compliance was triggered by the resignation of Mary Rotunno from the Board, effective April 1, 2026.
- The Audit Committee currently has two members, whereas Nasdaq requires at least three.
- The Company has a cure period to regain compliance, which expires at the earlier of the next annual meeting or April 1, 2027.
- The listing of the Company's common stock on The Nasdaq Capital Market is not immediately affected.
On March 17, 2026, Mary Rotunno resigned from the Board of Directors of Vistagen Therapeutics, Inc., effective April 1, 2026.
📋 Key Facts
- Mary Rotunno resigned from the Board of Directors on March 17, 2026.
- The resignation is scheduled to become effective on April 1, 2026.
- The filing does not disclose any disagreements between the director and the company.
Vistagen Therapeutics, Inc. furnished a new corporate presentation dated March 2026 under Regulation FD. This filing is a routine update of investor materials and does not report any material changes to operations or financial status.
📋 Key Facts
- The filing was made on March 16, 2026, under Item 7.01 Regulation FD Disclosure.
- The primary purpose is the release of a new corporate presentation (Exhibit 99.1).
- The information provided is 'furnished' and not 'filed' for purposes of Section 18 of the Exchange Act.
- The report was signed by CEO Shawn K. Singh.
Vistagen Therapeutics announced a 20% workforce reduction to preserve cash and prioritize its Phase 3 clinical program for fasedienol. The company expects topline results from its PALISADE-4 trial in H1 2026 and projects its cash runway will last into 2027.
🚩 Red Flags
- 20% workforce reduction indicates significant cost-cutting necessity.
- Concentration of resources on a single clinical program increases binary risk.
📋 Key Facts
- Implemented a 20% reduction in workforce on March 5, 2026.
- Prioritizing the PALISADE Program for fasedienol in social anxiety disorder.
- Topline results from PALISADE-4 Phase 3 trial expected in the first half of 2026.
- Projected cash runway extends into 2027.
- Severance and healthcare costs associated with the layoff are expected to be immaterial.
Vistagen Therapeutics disclosed the resignation of board director Paul Edick effective February 13, 2026. No reason was provided for the departure. The company stated it is actively seeking candidates to fill the resulting board vacancy.
🚩 Red Flags
- No reason provided for the board resignation — absence of standard 'no disagreement' language raises governance questions
- 7-day delay between resignation event (Feb 13) and filing date (Feb 20), though within the 4 business day SEC requirement
📋 Key Facts
- Paul Edick resigned from the Board of Directors on February 13, 2026
- No reason or context was provided for the resignation
- Company is actively seeking new candidates to fill the board vacancy
- Filing signed by CEO Shawn K. Singh on February 20, 2026 (7-day gap between event and filing)
- VTGN is listed on Nasdaq Capital Market, incorporated in Nevada, headquartered in South San Francisco